Novel therapeutic targets in rheumatoid arthritis: Trends in Pharmacological Sciences
IJMS | Free Full-Text | Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis | HTML
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot - Gastroenterology
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines | American Journal of Physiology-Gastrointestinal and Liver Physiology
The mechanism of action of tofacitinib. JAK: Janus family kinase. | Download Scientific Diagram
Pharmacology and safety of tofacitinib in ulcerative colitis | Gastroenterología y Hepatología (English Edition)
Current and future status of JAK inhibitors - The Lancet
The emerging safety profile of JAK inhibitors in rheumatic disease | Nature Reviews Rheumatology
Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata | Actas Dermo-Sifiliográficas
Biomolecules | Free Full-Text | JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future | HTML
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology. - Abstract - Europe PMC
Tofacitinib in ulcerative colitis | Immunotherapy
Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evid | DDDT
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19: Trends in Pharmacological Sciences
Figure 3 from The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. | Semantic Scholar
Frontiers | Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists | Pharmacology
References in JAK inhibitors in 2019, synthetic review in 10 points - European Journal of Internal Medicine
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache? | SpringerLink
Frontiers | Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies | Immunology
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib | Annals of the Rheumatic Diseases
Tofacitinib has a unique multitiered mechanism of action with an early... | Download Scientific Diagram
